Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Novel imaging platform reveals new details on aggressive cancer development

When cancers become aggressive and spread they are the most deadly. Unfortunately, little is known about how to stop this development. A new imaging platform developed by Lawson Health Research Institute's Drs. Ann Chambers and John Lewis is providing insight into just that - the exact moment when cancer cells turn deadly.

20 Jan 2012

HOXB13 gene mutation linked to familial prostate cancer risk

The quest for genetic information in the fight against prostate cancer is nearly two decades long. While researchers and doctors have long accepted the hereditary nature of the disease, in that closer relatives are at a two-fold increased risk of developing prostate cancer, the genetic explanation remained a mystery. Last week geneticists shared news of a novel gene mutation linked to familial prostate cancer risk.

19 Jan 2012

Economic burden of job-related injuries and illnesses in the U.S.

In the first comprehensive review of its kind since 1992, a UC Davis researcher has estimated the national annual price tag of occupational injuries and illnesses at $250 billion, much higher than generally assumed.

19 Jan 2012

Book outlines digital future of medicine

The inventions of cell phones, personal computers, and the Internet ushered in the digital revolution and altered our existence in ways that were unimaginable just a few decades ago. But the most precious part of our existence-our health-has so far been largely unaffected and insulated from these innovations.

19 Jan 2012

Viewpoints: Health care is a civil right; A Medicare strategy based on Lenin

Martin Luther King Jr.'s legacy is one of progress toward a better life for every American, including equal opportunity in voting, housing, education, and employment. Reflecting on his legacy also means recognizing the steps we must take to address the inequalities that persist. Many of these involve health care. Poor and minority Americans suffer from more preventable diseases on average, lower-quality care, fewer treatment options, and less health insurance coverage.

18 Jan 2012

Pfizer, Medivation report results from dimebon Phase 3 trial on AD

Medivation, Inc. and Pfizer Inc. today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease.

18 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012

Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients

Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.

13 Jan 2012

Genetic link to prostate cancer discovered

A new study has found that men who inherit a rare genetic mutation are 10 to 20 times more likely than average to develop prostate cancer. The gene variant may help explain cases of the disease that run in families and strike men at unusually young ages.

12 Jan 2012

Scientists identify rare genetic mutation linked to prostate cancer

After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease.

12 Jan 2012

DNA decoder – cheaper and faster

Life Technologies Corp. – a biotechnology company announced Tuesday that it has developed a machine to decode an individual's DNA in a day for just $1,000. The company said it was taking orders for the technology, which it expects to deliver in about a year. The Carlsbad, California, company said three major research institutions had already signed up for the $149,000 machine: the Baylor College of Medicine, the Yale School of Medicine and the Broad Institute of Cambridge, Massachusetts.

11 Jan 2012

Inherited breast and ovarian cancer drug trial re-launched in tablet form

Cancer Research UK's Drug Development Office has re-launched a trial of a promising drug to treat inherited breast and ovarian cancer - but this time taken as a tablet by outpatients.

11 Jan 2012

Obesity linked to higher rates of prostrate cancer screening across race/ethnicity and gender

Researchers in Family and Community Medicine at Thomas Jefferson University recently found that obesity was linked to higher rates of prostate cancer screening across all races/ethnic differences and lower rates of cervical cancer screening, most notably in white women.

10 Jan 2012

Researchers create prostate cancer drug delivery system

Honing chemotherapy delivery to cancer cells is a challenge for many researchers. Getting the cancer cells to take the chemotherapy "bait" is a greater challenge. But perhaps such a challenge has not been met with greater success than by the nanotechnology research team of Omid Farokhzad, MD, Brigham and Women's Hospital (BWH) Department of Anesthesiology Perioperative and Pain Medicine and Research.

10 Jan 2012

Noise-cancelling headphones may reduce pain and anxiety of prostate biopsy

Tuning in to tune out may be just what's needed for men undergoing a prostate biopsy, according to researchers at the Duke Cancer Institute. The Duke team found that noise-cancelling headphones playing a classical melody may reduce the pain and anxiety of the often uncomfortable procedure.

9 Jan 2012

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

Great Prostate Cancer Challenge 5K Race to take place in Fort Myers on Jan. 28

Lace up your sneakers and join Florida Urology Physicians and ZERO — The Project to End Prostate Cancer on Saturday, January 28, 2012 for the Great Prostate Cancer Challenge 5K Race in Fort Myers. The Great Prostate Cancer Challenge is America's premier men's health event series, taking place in 33 cities in 2012.

7 Jan 2012

Annual prostate cancer testing does not reduce mortality among men

Men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial had no evidence of a mortality benefit compared to a control group of men undergoing usual care, according to a study published online Jan. 6 in the Journal of the National Cancer Institute.

7 Jan 2012

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012